

Demonstrated experience in digital marketing, in particular the creation of marketing content both online and in print. [As part of your application for this position, please submit examples of content and/or marketing creation with your CV.]

1. World Microbiome Day Events for Cancer Research @UCC

Eventbrite Graphic



A4 Poster



Email Graphic



2. Social Media campaign promoting attendance of UCC Cancer Trials Group team at ASCO 2024

YouTube Video Watch a [short 11min video](#) I developed for the UCC CTG team outlining the social media communication plan for ASCO24 conference.

2024 ASCO[®]
ANNUAL MEETING

May 31 - June 4, 2024
Chicago, IL & Online

#ASCO24

**Kate O'Connell**
Evaluation of a complex survivorship intervention incorporating electronic patient-reported outcomes in early stage breast and gynecologic cancer: Results from the Linking You to Support and Advice (LYSA) randomized controlled trial. **Oral Session**
Abstract #1505

**Prof Jack Gleeson**
Linking in with advice and supports for men impacted by metastatic cancer: The LIAM Mc trial (NCT05946993). **Poster**
Poster Bd #513a

**Prof Seamus O'Reilly**
"Let's talk about sex, fertility and menopause": The Irish experience for those diagnosed with metastatic breast cancer (MBC) - An all-Ireland patient-led survey (CTRIAL-IE 23-05). **Poster**
Poster Bd #186

Climate therapy: Developing a climate change charter for Cancer Trials Ireland (CTI). **Publication**
Abstract #e23214

    

2024 ASCO[®]
ANNUAL MEETING

May 31 - June 4, 2024
Chicago, IL & Online

#ASCO24


Abstract #1505

ctg 

Oral Session
Survivorship Models of Care

🕒 **Tues 4 June 11:09 – 11:21 GMT-5**

Kate O'Connell

Evaluation of a complex survivorship intervention incorporating electronic patient-reported outcomes in early stage breast and gynecologic cancer: Results from the Linking You to Support and Advice (LYSA) randomized controlled trial.

  

2024 ASCO[®]
ANNUAL MEETING

May 31 - June 4, 2024
Chicago, IL & Online

#ASCO24


**Breakthrough
Cancer Research Fellow**



ctg 

Maev Hennessy

Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT Trial). **Poster**
Poster Bd 204b

Prospective Evaluation of the Breast Microbiome and Tumour Microenvironment-related Biomarkers of Response to Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer. **Poster**
Poster Bd 205a

RNA-Seq based gene expression profiling of base-line and on-treatment breast tumors to predict response to HER2- directed therapy, without chemotherapy; Translational Breast Cancer Research Consortium Trial 026. **Poster**
Poster Bd 122

  